- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Redhill Biopharma Ltd(RDHL)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for RDHL
11/20/2026: RDHL (1-star) is currently NOT-A-BUY. Pass it for now.
RedHill Biopharma is a micro-cap specialty biopharmaceutical company focused on commercializing gastrointestinal products and advancing a clinical pipeline. Its core strengths lie in recently acquired U.S. commercial rights for established therapies like Rebyota and Clenpiq, backed by targeted specialty promotion. The primary investment story centers on portfolio repositioning toward recurring revenue and pipeline catalysts in oncology and infectious diseases. However, key risks include financial constraints, execution uncertainties, and intense pharmaceutical competition. The stock suits high-risk growth investors willing to monitor commercial uptake, cash burn, and clinical milestones.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | While the pipeline offers potential expansion catalysts, the company's small scale and early-stage growth profile present execution uncertainties. |
| Momentum investor | Strong fit while signal remains positive | The stock can experience sharp episodic price movements around clinical updates, regulatory announcements, or corporate restructuring news. |
| Value investor | Weak fit | Negative net income and micro-cap valuation risks make traditional value assessment challenging. |
| Dividend investor | Weak fit | The company does not pay dividends, reinvesting capital into operations and development. |
| Low-risk investor | Weak fit | High share price volatility and micro-cap biotech risks expose investors to substantial capital loss. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Micro-cap biotechnology shares frequently exhibit extreme price fluctuations based on news flow and market sentiment. |
| Valuation risk | Medium / high | Uncertain future earnings and limited revenue scale make valuation support heavily dependent on execution. |
| Competition risk (specialty pharma and microbiome competition) | High | The company competes against well-funded pharmaceutical companies with established market shares. |
| Business quality | Medium | The business features approved commercial assets but remains constrained by micro-cap financial limitations. |
| Dividend income | Low / none | No dividend is paid to investors. |
| Execution risk | High | Success relies entirely on smoothly executing newly acquired commercial rights and advancing clinical trials. |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 2.50M USD | Price to earnings Ratio - | 1Y Target Price 19000 |
Price to earnings Ratio - | 1Y Target Price 19000 | ||
Volume (30-day avg) 91.9K shares | Beta 4.87 | 52 Weeks Range 0.28 - 1.42 | Updated Date 11/21/2026 |
52 Weeks Range 0.28 - 1.42 | Updated Date 11/21/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 55.2%
- Active BUY / eligible
- 53 / 96
- 30-Day BUY Count Change
- +19
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Drug Manufacturers - Specialty & Generic
- BUY participation
- 75.0%
- Active BUY / eligible
- 9 / 12
- 30-Day BUY Count Change
- +4
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Steep Decline
The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit -40.57% | Avg. Invested days 9 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Commercial Operations (United States) | Revenues generated from the U.S. promotion and sale of specialty gastrointestinal products like Rebyota and Clenpiq. | The primary stream comes from selling specialized prescription drugs in the U.S. market. |
| Licensing and Grants | Collaborative agreements, ex-U.S. licensing partnerships, and government research grants supporting pipeline programs. | Non-core funds come from research grants and partnership milestones. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 1428.57 | Enterprise Value -1.21M | Price to Sales(TTM) - |
Enterprise Value -1.21M | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 4.99 | Enterprise Value to EBITDA 0.3 | Shares Outstanding 8.89M | Shares Floating 4.20M |
Shares Outstanding 8.89M | Shares Floating 4.20M | ||
Percent Insiders - | Percent Institutions 4.62 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

